Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
The phase 3 clinical trial known as BEAT-meso, which combines chemotherapy plus bevacizumab with immunotherapy, has shown an improvement in overall survival (OS) and progression-free
One of the many services that the Meso Foundation offers to patients, caregivers, and the bereaved community is support groups offered over Zoom video conferencing.
In this episode of MesoTV, three patients, two with peritoneal mesothelioma and one with pleural mesothelioma, tell their stories of diagnosis, treatment, subsequent recurrence, and
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
